CVE-2025-15066 Details
Description
Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal'), Missing Authorization vulnerability in Innorix WP allows Path Traversal.This issue affects Innorix WP from All versions If the "exam" directory exists under the directory where the product is installed (ex: innorix/exam)
A path traversal vulnerability has been identified in Innorix WP, affecting all versions. This vulnerability allows for improper limitation of a pathname to a restricted directory, potentially leading to unauthorized access to files. The issue arises if the 'exam' directory exists under the installation directory of the product.
Metrics
CVSS 4.0 Severity and Vector Strings:
CVSS 3.x Severity and Vector Strings:
No data available for CVSS Version 2.0 on this CVE.
Volerion
Assessed Dec 29, 2025CISA-ADP
Assessed Dec 29, 2025References to Advisories, Solutions, and Tools
By selecting these links, you will be leaving this site. These are references gathered from the official CVE record and are not endorsed by Volerion.
| URL | Source(s) | Tag(s) |
|---|---|---|
| https://www.gnit.co.kr/software/innorix_product.html | FSI | ProductVendor |
| https://www.innorix.com/ | FSI | Broken LinkVendor |
Weakness Enumeration
| CWE-ID | CWE Name | Source |
|---|---|---|
| CWE-22 | Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') | FSI |
| CWE-862 | Missing Authorization | FSI |
Affected Products
| Product | Versions |
|---|---|
| Innorix WP | All versions |
CPE
Remediation
| |
Change History
3 change records found show changes
| Date | Action | Recorded By |
|---|---|---|
| Jun 17, 2026 | CVE Modified | FSI |
| Jun 17, 2026 | CVE Modified | CISA-ADP |
| Dec 29, 2025 | New CVE Received | FSI |
Volerion